Insider Selling: Liquidia Co. (NASDAQ:LQDA) Insider Sells $22,558.32 in Stock

Liquidia Co. (NASDAQ:LQDA) insider Rajeev Saggar sold 1,649 shares of the company’s stock in a transaction on Friday, April 19th. The shares were sold at an average price of $13.68, for a total value of $22,558.32. Following the transaction, the insider now directly owns 211,672 shares in the company, valued at approximately $2,895,672.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Liquidia Stock Performance

Shares of NASDAQ:LQDA opened at $12.37 on Friday. The company has a 50 day moving average price of $14.55 and a two-hundred day moving average price of $11.19. The company has a market capitalization of $940.47 million, a PE ratio of -10.31 and a beta of 0.16. Liquidia Co. has a 52 week low of $5.71 and a 52 week high of $16.99.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings data on Wednesday, March 13th. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.19). The firm had revenue of $4.53 million during the quarter, compared to the consensus estimate of $5.29 million. Liquidia had a negative net margin of 448.89% and a negative return on equity of 132.16%. On average, sell-side analysts forecast that Liquidia Co. will post -1.01 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its stake in Liquidia by 1.0% in the third quarter. Vanguard Group Inc. now owns 2,774,398 shares of the company’s stock valued at $17,590,000 after acquiring an additional 26,678 shares during the period. Kynam Capital Management LP grew its stake in Liquidia by 34.9% in the fourth quarter. Kynam Capital Management LP now owns 2,698,324 shares of the company’s stock valued at $32,461,000 after acquiring an additional 698,324 shares during the period. Vestal Point Capital LP acquired a new position in Liquidia in the fourth quarter valued at about $12,331,000. Beryl Capital Management LLC acquired a new position in Liquidia in the third quarter valued at about $3,135,000. Finally, LB Partners LLC acquired a new position in Liquidia in the fourth quarter valued at about $3,404,000. 64.54% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 price target on shares of Liquidia in a research note on Wednesday, April 10th. HC Wainwright upped their price target on Liquidia from $16.00 to $32.00 and gave the company a “buy” rating in a research note on Thursday, March 14th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $21.00.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).